Floatz logo

LEVODOPA

Visual Impairment

Qilu Hospital of Shandong UniversitySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Visual Impairment cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
University Hospital Freiburg
Phase 3B
FLUOXETINE
Bogachan Sahin
Phase 2CCC
Humax-Cd20
Johns Hopkins University
D
Sepofarsen
Laboratoires Thea
Phase 3NR

Same molecule, other indications

LEVODOPA is also rated in:

drug-induced dyskinesiaDormant
A
Indicative ·
80 / 100
View asset →
Parkinson diseaseDormant
BBB
Indicative ·
75 / 100
View asset →
movement disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →